{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005100","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.662788+00:00","generated_at":"2026-05-27T01:56:10.679956+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models","bullets":["KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.","In a preclinical study, KROS 101 reduced melanoma tumor in human GITR knock-in mouse model vs. the GITR antibody TRX518.","Data presented at the 13th AACR-JCA Joint Conference from Feb 1-5, 2025 in Maui, Hawaii.","CEO Dr. John S. Yu and VP R&D Dr. Ramachandran Murali co-presented; potential for melanoma and glioblastoma therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005100","json":"https://secwatch.observer/filing/0001493152-25-005100.json","markdown":"https://secwatch.observer/filing/0001493152-25-005100.md","text":"https://secwatch.observer/filing/0001493152-25-005100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/0001493152-25-005100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225005100/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:56:10.679956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}